Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Regenxbio Inc 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 USA

www.regenxbio.com P: 240-552-8181

Description:

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.

Key Statistics

Overview:

Market Capitalization, $K 786,650
Enterprise Value, $K 752,130
Shares Outstanding, K 49,043
Annual Sales, $ 90,240 K
Annual Net Income, $ -263,490 K
Last Quarter Sales, $ 22,210 K
Last Quarter Net Income, $ -62,890 K
EBIT, $ -268,130 K
EBITDA, $ -250,120 K
60-Month Beta 1.29
% of Insider Shareholders 13.13%
% of Institutional Shareholders 88.08%
Float, K 42,604
% Float 86.87%
Short Volume Ratio 0.45

Growth:

1-Year Return -15.17%
3-Year Return -53.76%
5-Year Return -68.90%
5-Year Revenue Growth -58.70%
5-Year Earnings Growth -352.94%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.43 on 02/27/24
Latest Earnings Date 05/01/24 [--]
Earnings Per Share ttm -6.03
EPS Growth vs. Prev Qtr -1.42%
EPS Growth vs. Prev Year -3.62%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

RGNX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -68.18%
Return-on-Assets % -39.95%
Profit Margin % -291.99%
Debt/Equity 0.00
Price/Sales 8.64
Price/Cash Flow N/A
Price/Book 2.21
Book Value/Share 7.09
Interest Coverage -37.43
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar